Adela announces closing of USD 48 million in financing

Adela, Inc. announced the closing of $48 million in financing. In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr Scott Bratman. Dr Bratman will continue to serve as a member of Adela’s Board of Directors and as President.

This $48 million financing includes existing investors F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management, as well as new investor Labcorp, a global leader of innovative and comprehensive laboratory services. It brings the total capital raised to date to $108 million.

The proceeds from the financing will be used to advance Adela’s technology platform and commercialize Adela’s first product for MRD monitoring. Adela’s tissue-agnostic MRD monitoring product is based on its genome-wide methylome enrichment platform, which efficiently captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. The proceeds will also be used to continue development of the company’s multi-cancer early detection (MCED) product, based on the same platform. Adela’s platform was originally developed by Adela’s Chief Scientific Officer, Daniel De Carvalho, Ph.D., at University Health Network’s Princess Margaret Cancer Centre, in collaboration with investigators at Sinai Health System.

“Adela’s genome-wide platform expands the potential opportunity for MRD testing through a novel methylome approach,” said Shakti Ramkissoon, M.D., Ph.D., Vice President and Head of Medicine for Oncology at Labcorp. “Bringing this highly differentiated offering to market means oncologists and patients will have a better understanding of MRD and how it impacts patients with cancer. Additionally, Adela’s work on multi-cancer early detection is exciting and has the potential to revolutionize the way early-stage cancer is detected.”

Lisa Alderson has been named Adela’s interim Chief Executive Officer. Alderson, a seasoned leader and operator who brings over 20 years of experience building early-stage companies at the intersection of technology and healthcare, has served on Adela’s Board of Directors since early 2022.

“We are excited to grow Adela to the next level with this new financing and the addition of Alderson’s expertise in commercializing healthcare products and scaling companies for growth,” said David Scheer, Chairman of Adela’s Board of Directors. “We look forward to bringing Adela’s MRD offering to market so that it can benefit patients”.

Alderson previously co-founded and served as the CEO of Genome Medical, the leading genomic care delivery company enabling broad-based access to genomic medicine. In addition, she served as the Chief Commercial Officer and Chief Strategy Officer of Invitae, and was also part of the start-up team at Genomic Health.

“During my tenure on the Board of Directors of Adela, I have been highly impressed with the talent, dedication, and passion of the Adela team, as well as with the unique ability of its genome-wide methylome enrichment platform to access expansive biological information cost-efficiently,” said Lisa Alderson, Interim CEO, Adela. “This round of financing enables us to prepare operationally to commercialize products that hold the potential to improve care for millions of people with cancer”.
MB Bureau